
 Substitute Form PTO-1449  
(Modified)

 U.S. Department of Commerce  
Patent and Trademark Office

 Attorney's Docket No.  
07039-351002

 Application No.  
10/796,522

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

37 CFR §1.98(b)

 Applicant  
Joseph F. Poduslo et al.

 Filing Date  
March 9, 2004

 Group Art Unit 1649
**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
/	AA	5,231,000	07/27/93	Majocha et al.	/	/	
	AB	5,262,332	11/16/93	Selkoe	/	/	
MA	AC	5,670,477	09/23/97	Poduslo et al.	/	/	
	AD	5,854,204	12/29/98	Findeis et al.	/	/	
/	AE	4,946,778	08/07/90	Ladner et al.	/	/	
/	AF	5,260,308	11/09/93	Poduslo et al.	/	/	
/	AG	5,604,198	02/18/97	Poduslo et al.	/	/	
/	AH	2004/0022736	02/05/04	Poduslo et al.	/	/	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
ju	AI	WO 01/74374	10/11/01	PCT				

**Other Documents (include Author, Title, Date, and Place of Publication)**


Examiner Initial	Desig. ID	Document
/	AJ	Caravan et al., "Gadolinium (III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications," <u>Chem. Rev.</u> , 1999, 99:2293-2352
	AK	Chen et al., "A learning deficit related to age and $\beta$ -amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 2000, 408:975-979
	AL	Curtet et al., "Polylysine-Gd-DTPA <sub>n</sub> and Polylysine-Gd-DOTA <sub>n</sub> Coupled to Anti-CEA F(ab') <sub>2</sub> Fragments as Potential Immunocontrast Agents," <u>Invest. Radiol.</u> , 1998, 33(10):752-761
ju	AM	De St. Groth and Scheidegger, "Production of Monoclonal Antibodies: Strategies and Tactics," <u>J. Immunol. Methods</u> , 1980, 35:1-21
/	AN	DeMattos et al., "Peripheral anti-A $\beta$ antibody alters CNS and plasma A $\beta$ clearance and decreases brain A $\beta$ burden in a mouse model of Alzheimer's disease," <u>Proc. Natl. Acad. Sci. USA</u> , 2001, 98(15):8850-8855
/	AO	Fraser et al., "Fibril Formation by Primate, Rodent, and Dutch-Hemorrhagic Analogues of Alzheimer Amyloid $\beta$ -Protein," <u>Biochemistry</u> , 1992, 31:10716-10723
/	AP	Hilbich et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 1991, 201:61-69
/	AQ	Janus et al., "A $\beta$ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 2000, 408:979-982
/	AR	Kalra, "Circumventing leptin resistance for weight control," <u>Proc. Natl. Acad. Sci. USA</u> , 2001, 98(8):4279-4281

Examiner Signature

Date Considered

4/19/2006

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Revised)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-351002	Application No. 10/796,522
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant Joseph F. Poduslo et al.	
		Filing Date March 9, 2004	Group Art Unit 1649

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
fl	AS	Lauffer et al., "Preparation and Water Relaxation Properties of Proteins Labeled with Paramagnetic Metal Chelates," <u>Magn. Reson. Imaging</u> , 1985, 3:11-16
	AT	Le et al., "Amyloid $\beta_{42}$ Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1," <u>J. Neuroscience</u> , 2001, 21:1-5
	AU	Morgan et al., "A $\beta$ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 2000, 408:982-985
	AV	Müller-Gartner, "Imaging techniques in the analysis of brain function and behaviour," <u>TIB Tech.</u> , 1998, 16:122-130
	AW	Poduslo and Curran, "Increased permeability across the blood-nerve barrier of albumin glycated <i>in vitro</i> and <i>in vivo</i> from patients with diabetic polyneuropathy," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89:2218-2222
	AX	Poduslo et al., "Macromolecular permeability across the blood-nerve and blood-brain barriers," <u>Proc. Natl. Acad. Sci. USA</u> , 1994, 91:5705-5709
	AY	Poduslo and Curran, "Polyamine Modification Increases the Permeability of Proteins at the Blood-Nerve and Blood-Brain Barriers," <u>J. Neurochemistry</u> , 1996, 66:1599-1609
	AZ	Poduslo et al., "Permeability of Proteins at the Blood-Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease," <u>Neurobiol. Disease</u> , 2001, 8:555-567
	AAA	Saito et al., "Vector-mediated delivery of $^{125}\text{I}$ -Labeled $\beta$ -amyloid peptide $\text{A}\beta^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the $\text{A}\beta^{1-40}$ /vector complex," <u>Proc. Natl. Acad. Sci. USA</u> , 1995, 92:10227-10231
	ABB	Saji, "Targeted Delivery of Radiolabeled Imaging and Therapeutic Agents: Bifunctional Radiopharmaceuticals," <u>Crit. Rev. Ther. Drug Carrier Syst.</u> , 1999, 16(2):209-244
	ACC	Sipkins et al., "Detection of tumor angiogenesis <i>in vivo</i> by $\alpha\beta_3$ -targeted magnetic resonance imaging," <u>Nature Med.</u> , 1998, 4(5):623-626
	ADD	Wang et al., "Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia," <u>Proc. Natl. Acad. Sci. USA</u> , 1999, 96:10373-10378
oc	AEE	Zanusso et al., "Prion protein expression in different species: Analysis with a panel of new mAbs," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:8812-8816

Examiner Signature <i>Weyman</i>	Date Considered 04/19/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	